The agreement marks a critical step in Phio's strategy to advance its PH-762 program, which utilizes the company's proprietary INTASYL® gene silencing technology. This technology is designed to enhance the immune system's ability to target and eliminate cancer cells. In previous trials, PH-762 has shown promising results, with a reported pathological response rate of approximately 65% across all dosing cohorts in its Phase 1b trial, including an impressive 85% response rate in the highest-dose cohort.
Phio's President and CEO, Robert Bitterman, expressed enthusiasm about the partnership, highlighting the strategic advantages of collaborating with a U.S.-based organization known for its quality and expertise in drug product manufacturing. This collaboration is expected to facilitate the production of PH-762 for both clinical and commercial supply, positioning Phio favorably as it prepares for future clinical trials.
Looking ahead, Phio has indicated that it plans to engage with the FDA regarding the next stages of clinical development in the second quarter of 2026. The company has also reported sufficient cash reserves to sustain operations into the first half of 2027, which provides a solid financial foundation as it moves forward with its clinical programs. Overall, this agreement is anticipated to have a noticeable positive effect on Phio's stock price as it demonstrates progress in its drug development pipeline and strengthens its operational capabilities.
